Stock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results

Stock Track

Jun 01

Revolution Medicines, Inc. (RVMD) experienced a significant surge of 17.76% during the night session trading, driven by positive developments related to its lead drug candidate.

The sharp increase follows the company's announcement of detailed results from its global Phase 3 RASolute 302 clinical trial evaluating daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma. Topline data from the study showed that daraxonrasib nearly doubled median overall survival compared to standard chemotherapy, extending it to 13.2 months versus 6.7 months for chemotherapy.

This breakthrough represents a significant advancement in pancreatic cancer treatment, where RAS mutations are highly prevalent but clinically validated targeted therapies have been scarce. The positive clinical data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal data and launch prospects for daraxonrasib.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1159329351"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1159329351\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1159329351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 15:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159329351","market":"hk","top_or_hot":-1,"title":"Stock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results","media":"Stock Track","content":"<p>Revolution Medicines, Inc. (RVMD) experienced a significant surge of 17.76% during the night session trading, driven by positive developments related to its lead drug candidate.</p><p>The sharp increase follows the company's announcement of detailed results from its global Phase 3 RASolute 302 clinical trial evaluating daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma. Topline data from the study showed that daraxonrasib nearly doubled median overall survival compared to standard chemotherapy, extending it to 13.2 months versus 6.7 months for chemotherapy.</p><p>This breakthrough represents a significant advancement in pancreatic cancer treatment, where RAS mutations are highly prevalent but clinically validated targeted therapies have been scarce. The positive clinical data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal data and launch prospects for daraxonrasib.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Revolution Medicines Soars 17.76% in Night Session on Positive Phase 3 Pancreatic Cancer Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-01 15:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Revolution Medicines, Inc. (RVMD) experienced a significant surge of 17.76% during the night session trading, driven by positive developments related to its lead drug candidate.</p><p>The sharp increase follows the company's announcement of detailed results from its global Phase 3 RASolute 302 clinical trial evaluating daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma. Topline data from the study showed that daraxonrasib nearly doubled median overall survival compared to standard chemotherapy, extending it to 13.2 months versus 6.7 months for chemotherapy.</p><p>This breakthrough represents a significant advancement in pancreatic cancer treatment, where RAS mutations are highly prevalent but clinically validated targeted therapies have been scarce. The positive clinical data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal data and launch prospects for daraxonrasib.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1159329351","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159329351","pubTimestamp":1780299440,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Revolution Medicines, Inc. (RVMD) experienced a significant surge of 17.76% during the night session trading, driven by positive developments related to its lead drug candidate.The sharp increase...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"个股追踪|Revolution Medicines夜盘大涨17.76%胰腺癌3期试验结果积极","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"Revolution Medicines, Inc. (RVMD) experienced a significant surge of 17.76% during the night session trading, driven by positive developments related to its lead drug candidate.The sharp increase follows the company's announcement of detailed results from its global Phase 3 RASolute 302 clinical trial evaluating daraxonrasib for the treatment of metastatic pancreatic ductal adenocarcinoma. Topline data from the study showed that daraxonrasib nearly doubled median overall survival compared to standard chemotherapy, extending it to 13.2 months versus 6.7 months for chemotherapy.This breakthrough represents a significant advancement in pancreatic cancer treatment, where RAS mutations are highly prevalent but clinically validated targeted therapies have been scarce. The positive clinical data has generated substantial market optimism, with analysts responding by reiterating Buy ratings and raising price targets based on the strong pivotal data and launch prospects for daraxonrasib.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}